Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab

Eosinophilic cellulitis (Wells syndrome [WS]) is a rare inflammatory skin disorder of unknown etiology. It is characterized by first edematous and later indurated plaques with eosinophilic infiltration of the dermis. In 1971 G.C. Wells first described the disease as recurrent granulomatous dermatitis with eosinophilia.1 To date, approximately 150 cases are reported. Trigger factors like insect bites, medications, infections, malignant tumors, or myeloproliferative disorders are discussed, but the exact etiology and pathogenesis of the disease are still unknown.2 We report a case of WS associated with bronchial asthma and successfully treated with mepolizumab, an anti–interleukin-5 humanized antibody.